Consylman Gina 4

What Happened
Gina Consylman, a director of Assembly Biosciences (ASMB), received a grant of stock options covering 8,000 shares on 2026-06-04. The Form 4 shows the acquisition price as $0.00 (standard notation for option grants) and lists the transaction as a derivative award rather than an open-market purchase or sale. No cash changed hands and there was no exercise or immediate sale reported.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (filed within the normal 2-business-day window).
• Transaction type/code: Award/Grant (A) — derivative security (stock options).
• Shares/options granted: 8,000 (acquisition at $0.00 as reported).
• Vesting: Options vest, assuming continuous service, on the earlier of (1) June 4, 2027 or (2) the issuer’s 2027 annual meeting of stockholders (per footnote).
• Shares owned after transaction: Not disclosed in the provided filing details.
• Exercise/strike price: Not specified in the provided excerpt (the $0.00 shown reflects the grant; it does not mean the exercise price is $0).

Context
This was a grant of stock options (an award), not an exercise or sale — meaning Consylman did not acquire underlying shares for trading immediately. Such grants are common for directors and are typically intended as compensation/alignment with shareholders; they do not by themselves indicate buying or selling sentiment.